-$1.22 Earnings Per Share Expected for Zai Lab Limited (NASDAQ:ZLAB) This Quarter

Equities analysts predict that Zai Lab Limited (NASDAQ:ZLABGet Rating) will post ($1.22) earnings per share for the current fiscal quarter, according to Zacks. Two analysts have issued estimates for Zai Lab’s earnings, with the highest EPS estimate coming in at ($0.93) and the lowest estimate coming in at ($1.50). Zai Lab posted earnings per share of ($2.64) in the same quarter last year, which suggests a positive year over year growth rate of 53.8%. The company is scheduled to issue its next quarterly earnings report after the market closes on Monday, January 1st.

On average, analysts expect that Zai Lab will report full-year earnings of ($4.10) per share for the current fiscal year, with EPS estimates ranging from ($6.47) to ($1.17). For the next year, analysts expect that the company will post earnings of ($2.72) per share, with EPS estimates ranging from ($5.71) to $1.56. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side analysts that cover Zai Lab.

Several analysts recently weighed in on ZLAB shares. Macquarie assumed coverage on Zai Lab in a report on Friday, January 21st. They set an “outperform” rating and a $64.00 price target for the company. SVB Leerink reduced their target price on shares of Zai Lab from $102.00 to $101.00 and set an “outperform” rating for the company in a research report on Thursday, April 21st. JPMorgan Chase & Co. decreased their target price on shares of Zai Lab from $136.00 to $112.00 and set an “overweight” rating on the stock in a research report on Monday, April 4th. Finally, Zacks Investment Research upgraded shares of Zai Lab from a “sell” rating to a “hold” rating in a research report on Thursday, April 7th. Two analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $127.00.

Shares of NASDAQ:ZLAB traded down $0.36 during trading on Wednesday, reaching $40.86. 6,729 shares of the stock were exchanged, compared to its average volume of 803,557. Zai Lab has a 12 month low of $25.74 and a 12 month high of $181.92. The stock has a 50-day moving average price of $44.28 and a 200-day moving average price of $62.25. The firm has a market cap of $3.94 billion, a PE ratio of -5.34 and a beta of 1.20.

In related news, Director John D. Diekman sold 1,000 shares of the company’s stock in a transaction on Friday, February 4th. The stock was sold at an average price of $50.17, for a total transaction of $50,170.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 6.26% of the stock is owned by corporate insiders.

A number of large investors have recently modified their holdings of the stock. CWM LLC acquired a new stake in Zai Lab in the fourth quarter valued at $35,000. Parallel Advisors LLC lifted its stake in shares of Zai Lab by 97.9% in the 4th quarter. Parallel Advisors LLC now owns 673 shares of the company’s stock valued at $42,000 after purchasing an additional 333 shares during the period. Quadrant Capital Group LLC lifted its stake in shares of Zai Lab by 50.9% in the 4th quarter. Quadrant Capital Group LLC now owns 1,198 shares of the company’s stock valued at $75,000 after purchasing an additional 404 shares during the period. Signaturefd LLC grew its stake in Zai Lab by 241.6% during the fourth quarter. Signaturefd LLC now owns 2,449 shares of the company’s stock worth $154,000 after purchasing an additional 1,732 shares during the period. Finally, Penserra Capital Management LLC grew its position in shares of Zai Lab by 13.6% during the 3rd quarter. Penserra Capital Management LLC now owns 1,585 shares of the company’s stock worth $167,000 after buying an additional 190 shares during the period. 66.97% of the stock is owned by institutional investors and hedge funds.

Zai Lab Company Profile (Get Rating)

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; and Qinlock to treat gastrointestinal stromal tumors.

Featured Stories

Get a free copy of the Zacks research report on Zai Lab (ZLAB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Zai Lab (NASDAQ:ZLAB)

Receive News & Ratings for Zai Lab Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zai Lab and related companies with MarketBeat.com's FREE daily email newsletter.